Journal
CLINICAL AND EXPERIMENTAL IMMUNOLOGY
Volume 125, Issue 1, Pages 3-9Publisher
BLACKWELL SCIENCE LTD
DOI: 10.1046/j.1365-2249.2001.01585.x
Keywords
cancer antigens; cancer autoimmunity; p62; CENP-F; hepatocellular carcinoma
Categories
Funding
- NCI NIH HHS [R01 CA056956, CA56956] Funding Source: Medline
Ask authors/readers for more resources
A feature of hepatocellular carcinoma (HCC) is that antecedent liver cirrhosis and chronic hepatitis are common precursor conditions and during transition to malignancy some patients develop autoantibodies which were not present during the preceding chronic liver disease phase. Serum samples from such patients can be used to immunoscreen cDNA expression libraries to identify genes encoding the new autoantigens. We demonstrate here the de novo appearance of antibodies to p62, a cytoplasmic protein which has been shown to bind to a developmentally regulated fetal species of insulin-like growth factor II (IGF-II) mRNA. Another antibody appearing during the transition period was against CENP-F, a cell cycle-related nuclear protein with maximum expression in the G2 and M phases of the cell cycle and previously shown to have a high association with malignancy. In three additional patients in whom serial serum samples were examined, new appearance of anti-p62 was detected in two patients and anti-CENP-F in one patient. This study demonstrates that transition to malignancy can be associated with autoantibody responses to certain cellular proteins which might have some role in tumorigenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available